Skip to main content
Zealand Pharma logo

Zealand Pharma — Investor Relations & Filings

Ticker · ZEAL ISIN · DK0060257814 LEI · 549300ITBB1ULBL4CZ12 CO Professional, scientific and technical activities
Open in API
Filings indexed 1,529 across all filing types
Latest filing 2019-05-16 Earnings Release
Country DK Denmark
Listing CO ZEAL

About Zealand Pharma

https://www.zealandpharma.com/

Zealand Pharma is a biotechnology company specializing in the discovery, design, and development of innovative peptide-based medicines. The company's primary focus is on advancing treatments for obesity and metabolic diseases, with a strategic goal to become a leader in this field. Its pipeline includes multiple candidates targeting obesity, such as petrelintide (a long-acting amylin analog) and survodutide (a glucagon/GLP-1 dual agonist licensed to a partner). Beyond metabolic health, Zealand Pharma develops therapies for rare diseases, including dasiglucagon for congenital hyperinsulinism and glepaglutide for short bowel syndrome. The company also has programs in chronic inflammation. Leveraging its expertise in peptide science, the company aims to create next-generation therapeutics to address significant unmet medical needs.

Recent filings

Filing Released Lang Actions
Earnings Release 2019
Earnings Release Classification · 99% confidence The document explicitly states it announces 'financial results for the quarter ended March 31, 2019' and provides detailed financial figures (Revenue, Net operating expenses, Net operating result, Cash position) for the 'first three months of 2019'. This content structure—quarterly financial highlights, business updates for the period, and guidance—is characteristic of an Earnings Release (ER). Although it mentions a conference call and refers to the Annual Report 2018 for guidance context, the primary purpose of this specific document is the initial announcement of period results, making 'ER' the most appropriate classification over 'IR' (Interim Report) because it focuses on the immediate release of results rather than being the comprehensive interim report itself, and it is clearly not a full 10-K. The presence of the conference call details further supports the ER classification. Q1 2019
2019-05-16 English
Zealand Pharma achieves primary and all key secondary endpoints in confirmatory Phase 3 trial with dasiglucagon for severe hypoglycemia
Regulatory Filings Classification · 90% confidence The document is a company announcement from Zealand Pharma regarding the successful results of a Phase 3 clinical trial for their drug 'dasiglucagon'. It details the trial endpoints, methodology, and clinical outcomes. This type of announcement, which provides updates on clinical development and research progress, does not fit into financial reporting categories like 10-K or IR, nor is it a simple report publication notice. It is a regulatory announcement regarding company operations and product development, which falls under the 'Regulatory Filings' (RNS) category as the most appropriate fallback for corporate news that does not fit specific financial or governance categories.
2019-05-14 English
Legal Proceedings Report 2019
Legal Proceedings Report Classification · 99% confidence The document is a company announcement (No. 15 / 2019) from Zealand Pharma detailing the successful results of a Phase 3 clinical trial for their drug dasiglucagon. It reports key scientific and medical outcomes (primary and secondary endpoints achieved, time to recovery, safety profile) and includes commentary from management. This content structure—announcing significant operational/clinical milestones rather than routine financial statements (like 10-K or IR) or mandatory voting results—is characteristic of an Earnings Release (ER) or a general corporate update. Since it focuses on clinical trial success, which is a major operational event, and is presented as a formal press release, it aligns best with the 'Earnings Release' category, which often encompasses major operational news releases, or potentially a Regulatory Filing (RNS) if it were less specific. Given the detailed nature of the results announcement, ER is a strong fit, although it is not strictly quarterly earnings. However, comparing the options, it is a direct announcement of a major business development/result. It is not a transcript (CT), a full annual report (10-K), or a proxy statement (PSI). It is a formal announcement of a key development, making ER the most appropriate fit among the provided choices for a major, non-financial results announcement, or RNS as a general regulatory/corporate announcement. Given the context of biotech/pharma, clinical trial success announcements are often treated as material news releases similar to earnings. I will classify it as an Earnings Release (ER) as it announces a major 'result' for the company, or RNS if ER is strictly for financial reporting. Since it is a formal announcement of a major milestone, RNS (Regulatory Filings - general fallback for material announcements) is safer, but ER often covers major operational successes. Let's re-evaluate: It is a press release announcing clinical trial success. This is material information. It is not a financial report (10-K, IR, MRQ). It is not a presentation (IP). It is a formal announcement. RNS is the best fit for a material, non-standard filing that doesn't fit the specific operational/governance codes.
2019-05-14 English
Zealand Pharma announces amendments to its Articles of Association following the granting of warrants
Share Issue/Capital Change Classification · 96% confidence The document is a company announcement regarding amendments to the Articles of Association following a grant of warrants and a subsequent share capital increase. This relates to changes in the company's capital structure and share issuance. According to the provided definitions, announcements regarding new share issues or capital changes fall under the 'SHA' category.
2019-04-17 English
Share Issue/Capital Change 2019
Share Issue/Capital Change Classification · 95% confidence The document is a company announcement from Zealand Pharma regarding amendments to its Articles of Association following the granting of warrants. This action directly relates to changes in the company's capital structure (share capital increase due to warrant grants). Among the provided definitions, 'Capital/Financing Update (CAP)' best describes an announcement concerning changes to the capital structure or financing activities, even if it's a technical amendment resulting from an incentive scheme. While it involves shares, it is not a direct share issue/buyback announcement (SHA/POS) but a structural change resulting from compensation/financing. Given the context of warrant grants leading to capital increase registration, CAP is the most appropriate fit over other structural changes.
2019-04-17 English
Handel med værdipapirer i Zealand Pharma A/S
Director's Dealing Classification · 100% confidence The document follows the standard template for 'notification and public disclosure of transactions by persons discharging managerial responsibilities' (PDMR). It identifies a specific board member (Hanne Heidenheim Bak) and details a transaction involving warrants (a grant). This is a classic 'Director's Dealing' notification, which is categorized under the DIRS code.
2019-04-10 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.